Response from hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Foster, Graham R ^a   Gore, Charles ^b   Hudson, Mark ^c   Moss, Peter ^d   Ustianowski, Andrew ^e   Ryder, Stephen ^f   Bhagani, Sanjay ^g  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Hepatitis C Trust   (United Kingdom)

^c BASL (British Association for the Study of the Liver)   (United Kingdom)

^d British Infection Association (BIA)   (United Kingdom)

^e British Viral Hepatitis Group (BVHG)   (United Kingdom)

^f British Society of Gastroenterology   (United Kingdom)

^g BHIVA Secretariat Mediscript Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; TELAPREVIR;

HEPATITIS C; HUMAN; LETTER; LIVER CANCER; LIVER CIRRHOSIS; MORTALITY; PRIORITY JOURNAL; SCREENING; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION; MASS SCREENING; PROCEDURES;

HEPATITIS C; HUMANS; MASS SCREENING;

EID: 84924204591     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h998     Document Type: Letter

References (6)

1. Koretz RL, Lin KW, Ioannidis JPA, Lenzer J. Is widespread screening for hepatitis C justified? BMJ 2015;350:g7809. (13 January.)
2. Razavi H, Waked I, Sarrazin C., Myers RP, Idilman R, Calinas F, et al The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014;21(SUPPL. 1):34-59.
3. Van der Meer AJ. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015;64:495-503.
4. Kraus MR, Schafer A, Teuber G., Porst H, Sprinzl K, Wollschlager S., et al Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. Hepatology 2013;58:497-504.
5. Poynard T, McHutchison J, Manns M., Trepo C, Lindsay K, Goodman Z., et al Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
6. Ferenci P, Bernstein D, Lalezari J., Cohen D, Luo Y, Cooper C., et al ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-92.